Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume – Should You Buy?

Pharvaris N.V. (NASDAQ:PHVS) saw unusually-strong trading volume on Tuesday . 611,090 shares traded hands during mid-day trading, an increase of 140% from the previous session’s volume of 254,849 shares.The stock last traded at $35.3840 and had previously closed at $34.71.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Cantor Fitzgerald reaffirmed its Buy rating on Pharvaris, reinforcing a bullish analyst view on the company’s longer-term potential. Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)
• Positive Sentiment: PHVS recently hit a new 1-year high, showing strong momentum and investor interest before the latest pullback. Pharvaris (NASDAQ:PHVS) Sets New 1-Year High – Still a Buy?
• Neutral Sentiment: Pharvaris reported a smaller-than-expected quarterly loss earlier this year, beating EPS estimates, which supports the underlying bullish case but did not create a fresh catalyst in the latest session.
• Negative Sentiment: Multiple insider sales by Anne Lesage and Director Johannes Gerardus Chri Schikan were disclosed over June 29-30, including sizable share disposals. Heavy insider selling can weigh on investor confidence and may be contributing to the stock’s weakness. SEC insider filing

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Wall Street Zen raised shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Wolfe Research started coverage on shares of Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Citigroup restated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, UBS Group set a $74.00 price target on shares of Pharvaris in a research report on Wednesday, May 13th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and a consensus price target of $49.64.

Pharvaris Price Performance

The stock’s fifty day simple moving average is $30.90 and its two-hundred day simple moving average is $28.21. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -10.66 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, sell-side analysts predict that Pharvaris N.V. will post -3.2 EPS for the current year.

Insider Transactions at Pharvaris

In other news, insider Peng Lu sold 15,000 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $30.24, for a total transaction of $453,600.00. Following the sale, the insider directly owned 66,083 shares in the company, valued at approximately $1,998,349.92. This represents a 18.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Glassman sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $29.82, for a total value of $298,200.00. Following the completion of the sale, the director directly owned 10,500 shares in the company, valued at approximately $313,110. This trade represents a 48.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 328,981 shares of company stock valued at $10,458,873 over the last ninety days. Insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP increased its position in Pharvaris by 472.3% in the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock worth $8,947,000 after buying an additional 261,355 shares during the period. DV Trading LLC acquired a new position in shares of Pharvaris during the first quarter valued at $4,067,000. Stempoint Capital LP boosted its holdings in shares of Pharvaris by 48.4% during the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock valued at $2,447,000 after acquiring an additional 28,248 shares during the period. ADAR1 Capital Management LLC grew its position in shares of Pharvaris by 23.4% during the first quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock worth $2,981,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Amundi grew its position in shares of Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company’s stock worth $874,000 after acquiring an additional 3,312 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.